Please upgrade your browser.
Despite sweltering conditions in Holuba Hall, the eighth annual Penn State Uplifting Athletes Lift For Life was a huge success drawing more than 3,000 fans and raising a record total of $98,461.35 to benefit the Kidney Cancer Association.
It may have been hot on Holuba Hall on Friday but that did not keep players form Penn State's football team from raising a record amount of money to be put toward kidney cancer research. More than 3,000 fans came out in support of the Nittany Lions as the team raised $98,461.35 for the Kidney Cancer Association.
Figlin, a prolific researcher known for his work on new urologic and lung cancer treatments, will help manage the institutes growing clinical trials program, in which more than 100 studies are being conducted. As leader of the hematology/oncology division, he will oversee breast, prostate, lung, blood and bone cancer programs.
The application of nanotechnology in the field of drug delivery has attracted much attention in recent years. In cancer research, nanotechnology holds great promise for the development of targeted, localized delivery of anticancer drugs, in which only cancer cells are affected.
Nate Stupar pours ice on his neck after completing the course during the Penn State Football Uplifting Athletes' Eighth Annual Lift for Life in Holuba Hall. Players form teams of four and compete in an 11 event challenge with exercises ranging from bench pressing to a giant tire flip. Proceeds from the event benefit the Kidney Cancer Association.
Galil Medical, a global leader in minimally invasive cryotherapy cancer treatments, today announced that Vanderbilt University Medical Center in Nashville, Tenn., has treated the first patient to be included in its new patient registry. The registry, called Tracking Renal Tumors After Cryoablation Evaluation (TRACE), will allow physicians and the company to follow and evaluate the use and effectiveness of cryotherapy treatment for patients with renal (kidney) tumors.
"We want to conquer kidney cancer in your lifetime," says KCA CEO Bill Bro, a 21-year survivor of kidney cancer. "Like many patients, my diagnosis came as the result of something unrelated. Because kidney cancer doesn't have obvious symptoms, it is often overlooked by both patients and doctors."
He told me I had a mass on my kidney, about 17 centimeters in size and it was called kidney cancer, recalled Kidwell.
Conclusion: Radical nephrectomy and level IV tumour thrombectomy is associated with significant mortality.
New findings from University Hospital, Department of Urology in the area of renal cell carcinoma described
Scientists discuss in 'Distant metastasis of renal cell carcinoma with a diameter of 3 cm or less-which is aggressive cancer' new findings in renal cell carcinoma.
|Powered by NeonCRM|